NCT04947124 2025-01-20
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Qlaris Bio, Inc.
Phase 2 Completed
Clinical Trials
4 trialsNCT05495269 2025-01-20
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Qlaris Bio, Inc.
Phase 2 Completed
NCT04447846 2023-05-25
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT01997255 2016-05-05
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Baylor College of Medicine
Phase 2 Withdrawn